UBS raises target to USD 735.00 for Madrigal Pharmaceuticals stock

Published on 10/17/2026 at 21:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS set F4 odds at 60.00 percent October 14, 2026. Madrigal Pharmaceuticals stock was USD 449.74 October 16, 2026, down 2.19 percent on Nasdaq.

Analyst valuation and operating scale

UBS raised its target from USD 669.00 to USD 735.00 on October 14, 2026.
Rezdiffra net sales reached USD 364.30 million in the second quarter of 2026, up 71.20 percent year over year.
Madrigal Pharmaceuticals stock stood at USD 449.74 on October 16, 2026 at 4:00 p.m. ET, down 2.19 percent versus the Nasdaq prior close.
Madrigal Pharmaceuticals had a USD 10.4 billion market capitalization and a negative P/E ratio of 34.89 on October 16, 2026.

MDGL, US5588681057, Illustration mit AI erstellt.

Madrigal Pharmaceuticals (US5588681057) stock came under a higher UBS valuation after the bank raised its target from USD 669.00 to USD 735.00 on October 14, 2026. The new target stood 63.43 percent above Madrigal's last Nasdaq price of USD 449.74 on October 16, 2026. Madrigal Pharmaceuticals stock last traded at USD 449.74 on October 16, 2026 at 4:00 p.m. ET, down 2.19 percent versus the Nasdaq prior close.

UBS raises the F4 probability

According to Investing.com on October 14, 2026, UBS lifted the price target while keeping a Buy rating. The firm also raised its estimated probability of success for Madrigal's F4 program from 20.00 percent to 60.00 percent. That change explains why the target distance matters more than the daily Nasdaq decline for this market report.

Rezdiffra sales reached USD 364.30 million

Madrigal's commercial picture supplied a second measurable reference. Investing.com reported that Rezdiffra net sales reached USD 364.30 million in the second quarter of 2026, up 71.20 percent from the year-earlier period and above the USD 350.85 million sales forecast cited in the report. The figure ties the analyst view to an operating metric rather than to valuation alone.

Price position and market value

The October 16, 2026 Nasdaq price of USD 449.74 was 14.26 percent above the 52-week low of USD 393.61 and 26.87 percent below the 52-week high of USD 615.00. Trading volume was 364,530 shares against an average of 292,387 shares on that date. Madrigal's market capitalization was USD 10.4 billion, while its trailing P/E ratio was negative 34.89.

Nasdaq listing and company scope

Madrigal is listed on Nasdaq under MDGL and develops therapies for metabolic dysfunction-associated steatohepatitis. Its investor-relations page describes Rezdiffra as its first therapy and identifies the company as focused on treatments for MASH. The Madrigal Pharmaceuticals investor page also identifies the Nasdaq listing and the company's therapeutic focus.

Stock level after the Nasdaq session

The combination of a USD 735.00 UBS target and USD 364.30 million second-quarter Rezdiffra sales gives investors two distinct measures for judging Madrigal's market position. The share price remains materially below the target while sitting above its 52-week low, and the negative P/E ratio reflects the company's reported loss position.